CN1295470A - 一种含有d2促进素的经由皮肤治疗帕金森氏症的体系及其制备方法 - Google Patents
一种含有d2促进素的经由皮肤治疗帕金森氏症的体系及其制备方法 Download PDFInfo
- Publication number
- CN1295470A CN1295470A CN99804751A CN99804751A CN1295470A CN 1295470 A CN1295470 A CN 1295470A CN 99804751 A CN99804751 A CN 99804751A CN 99804751 A CN99804751 A CN 99804751A CN 1295470 A CN1295470 A CN 1295470A
- Authority
- CN
- China
- Prior art keywords
- skin treating
- ethyl
- thienyl
- system via
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (17)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19814084A DE19814084B4 (de) | 1998-03-30 | 1998-03-30 | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
DE19814084.3 | 1998-03-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1295470A true CN1295470A (zh) | 2001-05-16 |
CN1142773C CN1142773C (zh) | 2004-03-24 |
Family
ID=7862904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998047511A Expired - Lifetime CN1142773C (zh) | 1998-03-30 | 1999-03-18 | 一种含有d2激动剂的经由皮肤治疗帕金森氏症的体系及其制备方法 |
Country Status (31)
Country | Link |
---|---|
US (4) | US6884434B1 (zh) |
EP (1) | EP1033978B1 (zh) |
JP (1) | JP3984785B2 (zh) |
KR (1) | KR100432276B1 (zh) |
CN (1) | CN1142773C (zh) |
AR (1) | AR014778A1 (zh) |
AT (1) | ATE210973T1 (zh) |
AU (1) | AU746856B2 (zh) |
BR (1) | BRPI9909313B8 (zh) |
CA (1) | CA2326630C (zh) |
CZ (1) | CZ297889B6 (zh) |
DE (4) | DE19814084B4 (zh) |
DK (1) | DK1033978T3 (zh) |
ES (1) | ES2170573T3 (zh) |
FR (1) | FR06C0025I2 (zh) |
HK (1) | HK1031196A1 (zh) |
HU (1) | HU226733B1 (zh) |
ID (1) | ID26646A (zh) |
IL (1) | IL138722A (zh) |
LU (1) | LU91269I2 (zh) |
MY (1) | MY119660A (zh) |
NL (1) | NL300236I2 (zh) |
NO (3) | NO325766B1 (zh) |
NZ (1) | NZ507066A (zh) |
PL (1) | PL193074B1 (zh) |
PT (1) | PT1033978E (zh) |
SK (1) | SK284618B6 (zh) |
TR (1) | TR200002829T2 (zh) |
TW (1) | TW579299B (zh) |
WO (1) | WO1999049852A1 (zh) |
ZA (1) | ZA200005261B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100333723C (zh) * | 2002-12-02 | 2007-08-29 | 施瓦茨制药有限公司 | 用于治疗帕金森病的罗替伐汀离子电渗给药 |
CN100430050C (zh) * | 2003-07-26 | 2008-11-05 | 施瓦茨制药有限公司 | 罗替戈汀用于生产治疗抑郁症的药物的用途 |
WO2009006787A1 (fr) * | 2007-07-06 | 2009-01-15 | Beijing Kangbeide Pharmaceutical Technology Development Co., Ltd. | Composition comprenant de la rotigotine, son utilisation et timbre transdermique comprenant la composition |
CN109806243A (zh) * | 2017-11-20 | 2019-05-28 | 北京泰德制药股份有限公司 | 一种含有氟吡汀或其药用盐的皮肤外用贴剂 |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19814084B4 (de) * | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
DE19918106A1 (de) | 1999-04-22 | 2000-10-26 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern |
JP4428899B2 (ja) | 1999-07-02 | 2010-03-10 | エルテーエス ローマン テラピー−ジステーメ アーゲー | ポリシロキサンおよび両親和性溶媒を基にした微小貯蔵所系 |
EP1233763B1 (de) * | 1999-11-29 | 2003-07-30 | LTS Lohmann Therapie-Systeme AG | Transdermale therapeutische systeme mit verbesserter stabilität und ein verfahren zu ihrer herstellung |
DE10054713C2 (de) * | 1999-11-29 | 2002-07-18 | Lohmann Therapie Syst Lts | Transdermale Therapeutische Systeme mit verbesserter Stabilität und ein Verfahren zu ihrer Herstellung |
DE10012908B4 (de) * | 2000-03-16 | 2005-03-17 | Lts Lohmann Therapie-Systeme Ag | Stabilisierte übersättigte transdermale therapeutische Matrixsysteme und Verfahren zu ihrer Herstellung |
AR030557A1 (es) | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
US6306403B1 (en) * | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
DE10041478A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
AU2005242160B2 (en) * | 2000-10-12 | 2009-02-26 | Lts Lohmann Therapie-Systeme Ag | Improved transdermal therapeutic system for the treatment of parkinson's disease |
US20030027793A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
US20030026830A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
ATE246919T1 (de) * | 2001-05-08 | 2003-08-15 | Sanol Arznei Schwarz Gmbh | Verbessertes transdermales therapeutisches system zur behandlung von morbus parkinson |
DK1256339T3 (da) * | 2001-05-08 | 2004-02-09 | Sanol Arznei Schwarz Gmbh | Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom |
DE10137082A1 (de) | 2001-07-28 | 2003-02-13 | Hexal Ag | Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol |
DE10141652B4 (de) * | 2001-08-24 | 2011-04-07 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung |
DE10159745A1 (de) | 2001-12-05 | 2003-07-03 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit verbessertem Langzeittragekomfort |
US20060263419A1 (en) * | 2002-03-12 | 2006-11-23 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
DE10220230A1 (de) * | 2002-05-06 | 2003-11-27 | Sanol Arznei Schwarz Gmbh | Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms |
US20040048779A1 (en) * | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
DE10234673B4 (de) * | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
US8246979B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
EP1386604A1 (en) * | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Improved transdermal delivery system |
EP1386605A1 (en) * | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Improved transdermal delivery system for the administration of rotigotine |
DE10261696A1 (de) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
MXPA05008366A (es) * | 2003-02-07 | 2005-11-04 | Lohmann Therapie Syst Lts | Sistema terapeutico transdermico adecuado para la aplicacion de calor para promover la penetracion de sustancias activas y el uso del mismo. |
DE10334187A1 (de) * | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
DE10359528A1 (de) * | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
EP1547592A1 (en) | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Intranasal formulation of rotigotine |
DE10361258A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
US20050197385A1 (en) * | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
DE102004014841B4 (de) * | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
JP2008514376A (ja) * | 2004-09-29 | 2008-05-08 | シュウォーツ ファーマ インコーポレイテッド | パーキンソン病のための経皮治療システム |
CA2548864C (en) * | 2005-06-06 | 2012-12-11 | Nitto Denko Corporation | Percutaneous absorption-type pharmaceutical preparation |
JP5025998B2 (ja) * | 2005-06-06 | 2012-09-12 | 日東電工株式会社 | 経皮吸収製剤 |
TWI392670B (zh) * | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的2-胺基萘滿之於製造用於預防、減緩及/或治療各種類型疼痛之藥物上的用途 |
DE102006028987A1 (de) * | 2006-06-24 | 2007-12-27 | Lts Lohmann Therapie-Systeme Ag | Ultraschallverstärktes transdermales therapeutisches System |
DE102006054732B4 (de) * | 2006-11-21 | 2010-12-30 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System mit Ionenpaar-Mikroreservoiren |
EP1987815A1 (en) * | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
WO2009063171A1 (en) * | 2007-11-16 | 2009-05-22 | Pliva Hrvatska D.O.O. | Novel rotigotine salts |
JP5391204B2 (ja) | 2007-11-28 | 2014-01-15 | ウーツェーベー ファルマ ゲーエムベーハー | ロチゴチンの多形体 |
US8580281B2 (en) * | 2008-02-27 | 2013-11-12 | Hisamitsu Pharmaceutical Co., Inc. | Medicated patch |
ES2661767T3 (es) | 2008-02-27 | 2018-04-03 | Hisamitsu Pharmaceutical Co., Inc. | Parche adhesivo para la piel y producto envasado |
DE102008013701A1 (de) * | 2008-03-11 | 2009-09-17 | Lts Lohmann Therapie-Systeme Ag | Transdermales Therapeutisches System mit stabilisierter Membran |
US20090247537A1 (en) * | 2008-03-25 | 2009-10-01 | William Dale Overfield | Methods for preventing or treating bruxism using dopaminergic agents |
US20110151001A1 (en) * | 2008-05-15 | 2011-06-23 | Nippon Zoki Pharmaceutical Co., Ltd. | Pharmaceutical composition for external application containing prochlorperazine |
DE102008060203A1 (de) | 2008-12-07 | 2010-06-10 | Dietrich Wilhelm Schacht | Wirkstoffstabilisierende flächenförmige Vorrichtung |
EP2201941A1 (de) * | 2008-12-29 | 2010-06-30 | UCB Pharma GmbH | Pflaster-Herstellungstechnologie |
DE102009022915A1 (de) * | 2009-05-27 | 2010-12-09 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System mit gesteuertem Wirkstofffluss |
EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
WO2011048491A2 (en) * | 2009-10-19 | 2011-04-28 | Actavis Group Ptc Ehf | Amorphous rotigotine co-precipitates |
CA2767068C (en) | 2009-12-22 | 2016-09-27 | Ucb Pharma Gmbh | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
EP2338873A1 (en) | 2009-12-22 | 2011-06-29 | Gmeiner, Peter | New aminotetraline derivatives |
EP2457565A1 (de) | 2010-11-29 | 2012-05-30 | Ratiopharm GmbH | Transdermales therapeutisches System enthaltend Rotigotin |
EA201300607A8 (ru) | 2010-12-02 | 2014-02-28 | Ратиофарм Гмбх | Ионная жидкость ротиготина |
WO2012084969A1 (en) | 2010-12-22 | 2012-06-28 | Hexal Ag | Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition |
WO2013020527A1 (en) | 2011-08-11 | 2013-02-14 | University Of Veterinary And Pharmaceutical Sciences Brno Faculty Of Pharmacy | Utilization of alaptide as transdermal penetration modifier in pharmaceutical compositions for human and veterinary applications containing anti-inflammatory drugs and/or antimicrobial chemotherapeutics |
EP2559435A1 (en) | 2011-08-19 | 2013-02-20 | UCB Pharma GmbH | Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke |
CN102499906B (zh) * | 2011-10-12 | 2013-04-17 | 长春健欣生物医药科技开发有限公司 | 一种罗替戈汀盐酸盐或自由碱成膜凝胶制剂及其制备方法 |
DE102011119043A1 (de) | 2011-11-22 | 2013-05-23 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System (TDS) mit Rotigotin |
DE102012013421A1 (de) | 2012-07-03 | 2014-01-09 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System (TTS) mit Rotigotin |
WO2013075822A1 (en) | 2011-11-22 | 2013-05-30 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermal therapeutic system (tts) with rotigotine |
DE102012013439A1 (de) | 2012-07-03 | 2014-01-23 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor |
DE102011090178A1 (de) * | 2011-12-30 | 2013-07-04 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation |
DE102012205493A1 (de) * | 2012-04-03 | 2013-10-10 | Acino Ag | Einen Dopamin-Agonisten enthaltendes transdermales Applikationssystem |
JP6180520B2 (ja) | 2012-07-05 | 2017-08-16 | エスケー ケミカルス カンパニー リミテッド | ロチゴチンを含有した経皮吸収製剤(Transdermalcompositioncomprisingrotigotine) |
EP2870963A4 (en) * | 2012-07-06 | 2016-03-09 | Sk Chemicals Co Ltd | PREPARATION CONTAINING ROTIGOTINE FOR PERCUTANEOUS ABSORBING |
TW201431570A (zh) * | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片 |
WO2014198422A1 (de) | 2013-06-14 | 2014-12-18 | Tesa Labtec Gmbh | Transdermales therapiesystem (tts) mit rotigotin |
US10046151B2 (en) | 2013-07-03 | 2018-08-14 | Lts Lohmann Therapie-Systeme, Ag | Transdermal therapeutic system with electronic component |
WO2015177212A1 (en) | 2014-05-20 | 2015-11-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an interface mediator |
ES2924899T3 (es) | 2014-05-20 | 2022-10-11 | Lts Lohmann Therapie Systeme Ag | Sistema de administración transdérmica que contiene rotigotina |
JP6895755B2 (ja) | 2014-05-20 | 2021-06-30 | エルテーエス ローマン テラピー−ジステーメ アーゲー | 経皮送達システムにおける活性薬剤の放出を調節するための方法 |
KR102364378B1 (ko) | 2014-05-21 | 2022-02-16 | 에스케이케미칼 주식회사 | 안정성을 향상시킨 로티고틴 함유 경피흡수제제 |
WO2016178876A2 (en) | 2015-05-01 | 2016-11-10 | Cocrystal Pharma, Inc. | Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer |
TWI754702B (zh) | 2016-12-28 | 2022-02-11 | 德商Ucb製藥有限公司 | (氮雜)吲哚-和苯並呋喃-3-磺醯胺類 |
WO2019124261A1 (ja) | 2017-12-19 | 2019-06-27 | 久光製薬株式会社 | ロチゴチン含有貼付剤 |
TW202016088A (zh) | 2018-06-19 | 2020-05-01 | 德商Ucb製藥有限公司 | 吡啶基及吡基-(氮)吲哚磺醯胺 |
EP3584244A1 (en) | 2018-06-20 | 2019-12-25 | UCB Pharma GmbH | Substituted alkoxypyridinyl indolsulfonamides |
KR20200046461A (ko) | 2018-10-24 | 2020-05-07 | 에스케이케미칼 주식회사 | 비결정 로티고틴 함유 조성물 및 이의 제조 방법 |
CN113453676A (zh) | 2019-02-15 | 2021-09-28 | 久光制药株式会社 | 罗替戈汀稳定化方法 |
ES2962896T3 (es) | 2019-06-14 | 2024-03-21 | Hisamitsu Pharmaceutical Co | Parche que contiene rotigotina |
EP3983384B1 (en) | 2019-06-17 | 2023-10-11 | UCB Pharma GmbH | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis |
EP3854388B1 (de) | 2020-01-24 | 2023-10-04 | Luye Pharma Switzerland AG | Transdermales therapeutisches system mit dem wirkstoff rotigotin und mindestens einem nicht aminresistenten silikonkleber |
CN113368083A (zh) * | 2021-06-16 | 2021-09-10 | 华健医疗(深圳)有限公司 | 一种大麻二酚cbd透皮给药系统 |
Family Cites Families (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5177112A (en) * | 1983-01-03 | 1993-01-05 | Whitby Research, Inc. | Substituted 2-aminotetralins |
US5268385A (en) | 1983-01-03 | 1993-12-07 | Whitby Research, Inc. | Method for treating schizophrenia |
US4655767A (en) | 1984-10-29 | 1987-04-07 | Dow Corning Corporation | Transdermal drug delivery devices with amine-resistant silicone adhesives |
US4863970A (en) * | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
US5273757A (en) * | 1987-09-01 | 1993-12-28 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Apparatus for the delivery of substances, processes for the production thereof and use thereof |
US4915950A (en) * | 1988-02-12 | 1990-04-10 | Cygnus Research Corporation | Printed transdermal drug delivery device |
US5656286A (en) * | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US4942037A (en) * | 1988-06-02 | 1990-07-17 | Merck & Co., Inc. | Transdermal delivery systems |
DE3827561C1 (zh) * | 1988-08-13 | 1989-12-28 | Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De | |
DE69009540T2 (de) * | 1989-03-15 | 1994-09-29 | Nitto Denko Corp | Arzneimittel enthaltendes Heftpflaster. |
US4973468A (en) * | 1989-03-22 | 1990-11-27 | Cygnus Research Corporation | Skin permeation enhancer compositions |
FR2648131B1 (fr) * | 1989-06-13 | 1991-10-18 | Oreal | Nouveaux derives de tetrahydro -5,6,7,8 naphtalenol-1, leur procede de preparation et leur utilisation en tant qu'agents antioxydants dans des compositions cosmetiques et pharmaceutiques les contenant |
US5252335A (en) * | 1989-07-12 | 1993-10-12 | Cygnus Therapeutic Systems | Transdermal administration of lisuride |
US5091186A (en) * | 1989-08-15 | 1992-02-25 | Cygnus Therapeutic Systems | Biphasic transdermal drug delivery device |
US5124157A (en) * | 1989-08-18 | 1992-06-23 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
US5252334A (en) * | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
US5271940A (en) * | 1989-09-14 | 1993-12-21 | Cygnus Therapeutic Systems | Transdermal delivery device having delayed onset |
DE3933460A1 (de) * | 1989-10-06 | 1991-04-18 | Lohmann Therapie Syst Lts | Oestrogenhaltiges wirkstoffpflaster |
US5147916A (en) * | 1990-02-21 | 1992-09-15 | Dow Corning Corporation | Hot-melt silicone pressure sensitive adhesive composition and related methods and articles |
US5246997A (en) * | 1990-02-21 | 1993-09-21 | Dow Corning Corporation | Method of making a hot-melt silicone pressure sensitive adhesive-coated substrate |
US5069909A (en) * | 1990-06-20 | 1991-12-03 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine |
US5382569A (en) * | 1991-05-16 | 1995-01-17 | Warner-Lambert Company | Endotherlin antagonists |
US5232702A (en) * | 1991-07-22 | 1993-08-03 | Dow Corning Corporation | Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices |
US5273755A (en) * | 1991-08-23 | 1993-12-28 | Cygnus Therapeutic Systems | Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset |
US5234690A (en) * | 1991-08-23 | 1993-08-10 | Cygnus Therapeutic Systems | Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset |
US5273756A (en) * | 1991-08-23 | 1993-12-28 | Cygnus Therapeutic Systems | Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset |
AU2514292A (en) * | 1991-08-27 | 1993-03-16 | Cygnus Therapeutic Systems | Transdermal formulations for administering prazosin |
US5225198A (en) * | 1991-08-27 | 1993-07-06 | Cygnus Therapeutic Systems | Transdermal administration of short or intermediate half-life benzodiazepines |
AU2782592A (en) | 1991-10-15 | 1993-05-21 | Cygnus Therapeutic Systems | Thermal enhancement of transdermal drug administration |
WO1993014727A1 (en) | 1992-01-31 | 1993-08-05 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine in the form of ion pair complexes |
GB9202915D0 (en) | 1992-02-12 | 1992-03-25 | Wellcome Found | Chemical compounds |
EP0656771A4 (en) | 1992-08-25 | 1996-07-31 | Cygnus Therapeutic Systems | DEVICE FOR TRANSDERMAL DRUG DELIVERY. |
US5308625A (en) * | 1992-09-02 | 1994-05-03 | Cygnus Therapeutic Systems | Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters |
US5989586A (en) * | 1992-10-05 | 1999-11-23 | Cygnus, Inc. | Two-phase matrix for sustained release drug delivery device |
US5462746A (en) * | 1992-11-02 | 1995-10-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation |
DE4301781C2 (de) * | 1993-01-23 | 1995-07-20 | Lohmann Therapie Syst Lts | Nitroglycerinhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung |
CA2166191A1 (en) | 1993-06-24 | 1995-01-05 | Dan W. Connors | Transdermal delivery system package |
CA2166780A1 (en) | 1993-07-08 | 1995-01-19 | Ooi Wong | Monolithic matrix transdermal delivery system |
US5382596A (en) * | 1993-08-05 | 1995-01-17 | Whitby Research, Inc. | Substituted 2-aminotetralins |
US5554381A (en) * | 1993-08-09 | 1996-09-10 | Cygnus, Inc. | Low flux matrix system for delivering potent drugs transdermally |
WO1995005138A1 (en) | 1993-08-16 | 1995-02-23 | Cygnus Therapeutic Systems | Contact adhesive extends wear time on skin |
AU7517794A (en) | 1993-08-16 | 1995-03-14 | Cygnus Therapeutic Systems | Transdermal delivery system using a combination of permeation enhancers |
CN1099663C (zh) | 1994-03-11 | 2003-01-22 | 皇家菲利浦电子有限公司 | 准周期信号的传输系统 |
EP1016433A1 (en) | 1994-06-24 | 2000-07-05 | Cygnus, Inc. | Iontophoteric sampling device and method |
US5771890A (en) * | 1994-06-24 | 1998-06-30 | Cygnus, Inc. | Device and method for sampling of substances using alternating polarity |
GB2290964A (en) * | 1994-07-08 | 1996-01-17 | Arto Olavi Urtti | Transdermal drug delivery system |
US6024974A (en) * | 1995-01-06 | 2000-02-15 | Noven Pharmaceuticals, Inc. | Composition and methods for transdermal delivery of acid labile drugs |
AU4761196A (en) | 1995-01-19 | 1996-08-07 | Cygnus, Inc. | Polymer adhesive formulation containing sorbent particles |
WO1996022083A1 (en) | 1995-01-19 | 1996-07-25 | Cygnus, Inc. | POLYISOBUTYLENE ADHESIVES CONTAINING HIGH Tg TACKIFIER FOR TRANSDERMAL DEVICES |
US5601839A (en) * | 1995-04-26 | 1997-02-11 | Theratech, Inc. | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
GB9511366D0 (en) * | 1995-06-06 | 1995-08-02 | Smithkline Beecham Plc | Novel formulations |
UA48973C2 (uk) * | 1995-06-07 | 2002-09-16 | Орто-Макнейл Фармасьютікалз Інк. | Трансдермальний пластир на основі 17-деацетилноргестимату для попередження овуляції |
US6316022B1 (en) * | 1995-06-07 | 2001-11-13 | Noven Pharmaceuticals, Inc. | Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures |
WO1996040087A2 (en) | 1995-06-07 | 1996-12-19 | Cygnus, Inc. | Pressure sensitive acrylate adhesive composition cross-linked with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group |
US5906830A (en) * | 1995-09-08 | 1999-05-25 | Cygnus, Inc. | Supersaturated transdermal drug delivery systems, and methods for manufacturing the same |
WO1997009971A2 (en) | 1995-09-14 | 1997-03-20 | Cygnus, Inc. | High capacity, superabsorbent drug reservoirs for use in transdermal drug delivery systems |
US5902603A (en) * | 1995-09-14 | 1999-05-11 | Cygnus, Inc. | Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use |
US5891461A (en) * | 1995-09-14 | 1999-04-06 | Cygnus, Inc. | Transdermal administration of olanzapine |
US6063398A (en) * | 1995-09-20 | 2000-05-16 | L'oreal | Cosmetic or dermopharmaceutical patch containing, in an anhydrous polymeric matrix, at least one active compound which is, in particular, unstable in oxidizing mediums, and at least one water-absorbing agent |
US5807570A (en) * | 1995-09-29 | 1998-09-15 | Cygnus, Inc. | Transdermal administration of ropinirole and analogs thereof |
US5733571A (en) * | 1995-12-08 | 1998-03-31 | Euro-Celtique, S.A. | Transdermal patch for comparative evaluations |
AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
US5843472A (en) * | 1997-02-28 | 1998-12-01 | Cygnus, Inc. | Transdermal drug delivery sytem for the administration of tamsulosin, and related compositions and methods of use |
US5879701A (en) * | 1997-02-28 | 1999-03-09 | Cygnus, Inc. | Transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizing agents |
DE19814084B4 (de) * | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
DE19814083C2 (de) * | 1998-03-30 | 2002-02-07 | Lohmann Therapie Syst Lts | Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen |
ATE220936T1 (de) * | 1998-05-13 | 2002-08-15 | Cygnus Therapeutic Systems | Sammelvorrichtungen für transdermale probennahmesysteme |
DE19828273B4 (de) * | 1998-06-25 | 2005-02-24 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren |
DE69913153D1 (de) * | 1998-09-17 | 2004-01-08 | Cygnus Therapeutic Systems | Gerät zum zusammendrücken einer gel/sensor-einheit |
FR2792529B1 (fr) | 1999-04-26 | 2001-09-28 | Sod Conseils Rech Applic | Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines |
AU5325000A (en) * | 1999-06-05 | 2000-12-28 | David Houze | Solubility enhancement of drugs in transdermal drug delivery systems and methodsof use |
US6218421B1 (en) * | 1999-07-01 | 2001-04-17 | Smithkline Beecham P.L.C. | Method of promoting smoking cessation |
DE19940238A1 (de) * | 1999-08-25 | 2001-03-01 | Lohmann Therapie Syst Lts | Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten |
KR100317533B1 (ko) * | 1999-11-10 | 2001-12-24 | 윤종용 | 반도체 집적회로 장치에서의 레이저 퓨즈박스의 구조 및그에 따른 제조 방법 |
US6372920B1 (en) * | 1999-11-23 | 2002-04-16 | Aderis Pharmaceuticals, Inc. | Process for preparing nitrogen-substituted aminotetralins |
EP1233763B1 (de) * | 1999-11-29 | 2003-07-30 | LTS Lohmann Therapie-Systeme AG | Transdermale therapeutische systeme mit verbesserter stabilität und ein verfahren zu ihrer herstellung |
US20020110585A1 (en) * | 1999-11-30 | 2002-08-15 | Godbey Kristin J. | Patch therapeutic agent delivery device having texturized backing |
DE10018467A1 (de) | 2000-04-14 | 2001-10-25 | Bosch Gmbh Robert | Elektrische Maschine |
DE10041478A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
US20020119187A1 (en) * | 2000-09-29 | 2002-08-29 | Cantor Adam S. | Composition for the transdermal delivery of fentanyl |
DE10060550C1 (de) * | 2000-12-06 | 2002-04-18 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten |
US20030026830A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
US20030027793A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
FR2829028B1 (fr) * | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
US20060263419A1 (en) * | 2002-03-12 | 2006-11-23 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
MXPA04009352A (es) * | 2002-04-18 | 2005-01-25 | Pharmacia Corp | Terapia de combinacion para el tratamiento de la enfermedad de parkinson con inhibidores de ciclooxigenasa-2 (cox2). |
US20040048779A1 (en) * | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
US20060216336A1 (en) | 2002-05-07 | 2006-09-28 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
KR20050045946A (ko) * | 2002-06-25 | 2005-05-17 | 애크럭스 디디에스 피티와이 리미티드 | 비정질 약학적 조성물을 이용한 경피전달속도의 제어 |
US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
DE10234673B4 (de) * | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
US8246979B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
ATE295726T1 (de) * | 2002-12-02 | 2005-06-15 | Sanol Arznei Schwarz Gmbh | Verabreichung von rotigotine zur behandlung der parkinson'schen krankheit durch iontophorese |
US9102726B2 (en) * | 2002-12-04 | 2015-08-11 | Argos Therapeutics, Inc. | Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same |
DE10261696A1 (de) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
DE10334187A1 (de) | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
DE10334188B4 (de) | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
US7379762B2 (en) | 2003-09-04 | 2008-05-27 | Creative Technology Ltd. | Portable digital device orientation |
DE10359528A1 (de) | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
EP1547592A1 (en) * | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Intranasal formulation of rotigotine |
DE10361258A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
US20050197385A1 (en) * | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
DE102004014841B4 (de) * | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
US20060024362A1 (en) | 2004-07-29 | 2006-02-02 | Pawan Seth | Composition comprising a benzimidazole and process for its manufacture |
TWI392670B (zh) | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的2-胺基萘滿之於製造用於預防、減緩及/或治療各種類型疼痛之藥物上的用途 |
EP1987815A1 (en) * | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
JP5391204B2 (ja) | 2007-11-28 | 2014-01-15 | ウーツェーベー ファルマ ゲーエムベーハー | ロチゴチンの多形体 |
EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
CA2767068C (en) | 2009-12-22 | 2016-09-27 | Ucb Pharma Gmbh | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
-
1998
- 1998-03-30 DE DE19814084A patent/DE19814084B4/de not_active Expired - Lifetime
-
1999
- 1999-03-18 IL IL13872299A patent/IL138722A/xx not_active IP Right Cessation
- 1999-03-18 PT PT99910359T patent/PT1033978E/pt unknown
- 1999-03-18 CN CNB998047511A patent/CN1142773C/zh not_active Expired - Lifetime
- 1999-03-18 HU HU0101519A patent/HU226733B1/hu active Protection Beyond IP Right Term
- 1999-03-18 AU AU29341/99A patent/AU746856B2/en not_active Expired
- 1999-03-18 DK DK99910359T patent/DK1033978T3/da active
- 1999-03-18 KR KR10-2000-7010896A patent/KR100432276B1/ko active Protection Beyond IP Right Term
- 1999-03-18 AT AT99910359T patent/ATE210973T1/de active
- 1999-03-18 DE DE122006000035C patent/DE122006000035I2/de active Active
- 1999-03-18 EP EP99910359A patent/EP1033978B1/de not_active Expired - Lifetime
- 1999-03-18 DE DE1999500581 patent/DE122006000035I1/de active Pending
- 1999-03-18 TR TR2000/02829T patent/TR200002829T2/xx unknown
- 1999-03-18 ID IDW20001959A patent/ID26646A/id unknown
- 1999-03-18 WO PCT/EP1999/001795 patent/WO1999049852A1/de active IP Right Grant
- 1999-03-18 PL PL343255A patent/PL193074B1/pl unknown
- 1999-03-18 JP JP2000540818A patent/JP3984785B2/ja not_active Expired - Lifetime
- 1999-03-18 SK SK1446-2000A patent/SK284618B6/sk not_active IP Right Cessation
- 1999-03-18 DE DE59900581T patent/DE59900581D1/de not_active Expired - Lifetime
- 1999-03-18 CA CA002326630A patent/CA2326630C/en not_active Expired - Lifetime
- 1999-03-18 CZ CZ20003581A patent/CZ297889B6/cs not_active IP Right Cessation
- 1999-03-18 NZ NZ507066A patent/NZ507066A/xx not_active IP Right Cessation
- 1999-03-18 BR BRPI9909313A patent/BRPI9909313B8/pt not_active IP Right Cessation
- 1999-03-18 ES ES99910359T patent/ES2170573T3/es not_active Expired - Lifetime
- 1999-03-18 US US09/647,290 patent/US6884434B1/en not_active Expired - Lifetime
- 1999-03-26 AR ARP990101336A patent/AR014778A1/es active IP Right Grant
- 1999-03-26 MY MYPI99001191A patent/MY119660A/en unknown
- 1999-07-17 TW TW088104112A patent/TW579299B/zh not_active IP Right Cessation
-
2000
- 2000-09-29 NO NO20004915A patent/NO325766B1/no not_active IP Right Cessation
- 2000-09-29 ZA ZA200005261A patent/ZA200005261B/xx unknown
-
2001
- 2001-02-07 HK HK01100865A patent/HK1031196A1/xx unknown
-
2004
- 2004-09-07 US US10/936,620 patent/US10322093B2/en not_active Expired - Fee Related
-
2006
- 2006-07-26 LU LU91269C patent/LU91269I2/fr unknown
- 2006-07-28 FR FR06C0025C patent/FR06C0025I2/fr active Active
- 2006-08-01 NL NL300236C patent/NL300236I2/nl unknown
-
2007
- 2007-10-31 US US11/931,666 patent/US7413747B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/931,762 patent/US10251844B2/en not_active Expired - Lifetime
-
2008
- 2008-01-25 NO NO20080489A patent/NO20080489L/no unknown
- 2008-10-14 NO NO2008014C patent/NO2008014I2/no unknown
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100333723C (zh) * | 2002-12-02 | 2007-08-29 | 施瓦茨制药有限公司 | 用于治疗帕金森病的罗替伐汀离子电渗给药 |
CN100430050C (zh) * | 2003-07-26 | 2008-11-05 | 施瓦茨制药有限公司 | 罗替戈汀用于生产治疗抑郁症的药物的用途 |
WO2009006787A1 (fr) * | 2007-07-06 | 2009-01-15 | Beijing Kangbeide Pharmaceutical Technology Development Co., Ltd. | Composition comprenant de la rotigotine, son utilisation et timbre transdermique comprenant la composition |
US9265752B2 (en) | 2007-07-06 | 2016-02-23 | Jiangsu Kangbeide Pharmaceuticals Co. Ltd. | Transdermal patch containing Rotigotine |
CN109806243A (zh) * | 2017-11-20 | 2019-05-28 | 北京泰德制药股份有限公司 | 一种含有氟吡汀或其药用盐的皮肤外用贴剂 |
CN109806243B (zh) * | 2017-11-20 | 2022-07-15 | 北京泰德制药股份有限公司 | 一种含有氟吡汀或其药用盐的皮肤外用贴剂 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1142773C (zh) | 一种含有d2激动剂的经由皮肤治疗帕金森氏症的体系及其制备方法 | |
US10709669B2 (en) | Microreservoir system based on polysiloxanes and ambiphilic solvents | |
US8277838B2 (en) | Transdermal delivery of drugs based on crystal size | |
RU2356580C2 (ru) | Композиции и способы, обеспечивающие контролируемую потерю лекарственных средств и доставку в системах трансдермальной доставки лекарственных средств | |
JP2004514738A (ja) | 活性物質としてオキシブチニンで構成される経皮治療システム | |
WO2009006787A1 (fr) | Composition comprenant de la rotigotine, son utilisation et timbre transdermique comprenant la composition | |
CN1281209C (zh) | 稳定的过饱和经皮肤治疗基质系统 | |
KR100685553B1 (ko) | 폴리실록산 및 양친매성 용매를 기초로 한 미소저장기 시스템 | |
CN101431988A (zh) | 包含东莨菪碱的透皮治疗系统 | |
WO2009106831A2 (en) | Pharmaceutical composition | |
MXPA00009570A (en) | Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20081226 Address after: German Adner Beh Co-patentee after: Schwartz pharmaceuticals Ltd Patentee after: LTS Norman medical systems limited liability company Address before: German Adner Beh Co-patentee before: Adris pharmaceutical limited liability company Patentee before: LTS Norman medical systems limited liability company |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: German Adner Beh Co-patentee after: UCB manufacturing Ireland Ltd Patentee after: LTS Lohman Therapie-System AG Address before: German Adner Beh Co-patentee before: Schwartz pharmaceuticals Ltd Patentee before: LTS Lohman Therapie-System AG |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20040324 |